Genomic loss of heterozygosity and survival in the REAL3 trial

BACKGROUND: Homologous recombination deficiency (HRD) measured using a genomic signature for loss of heterozygosity (LOH) predicts benefit from rucaparib in ovarian cancer. We hypothesized that some oesophagogastric cancers will have high-LOH which would be prognostic in patients treated with platin...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Oncotarget
Asıl Yazarlar: Smyth, Elizabeth C., Cafferkey, Catherine, Loehr, Andrea, Waddell, Tom, Begum, Ruwaida, Peckitt, Clare, Harding, Thomas C., Nguyen, Minh, Okines, Alicia F., Raponi, Mitch, Rao, Sheela, Watkins, David, Starling, Naureen, Middleton, Gary W., Wadsley, Jonathan, Mansoor, Wasat, Crosby, Tom, Wotherspoon, Andrew, Chau, Ian, Cunningham, David
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Impact Journals LLC 2018
Konular:
Research Paper
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6291175/
https://ncbi.nlm.nih.gov/pubmed/30613349
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.26336
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller